Leucine rich repeat kinase 2 and dominantly inherited Parkinson disease
Leucine rich repeat kinase 2 and dominantly inherited Parkinson disease
批准号:
8552524
负责人:
Mark Cookson
金额:
$64.96万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Biological ModelsCellsComplexDiseaseGenesGeneticHomologous GeneInheritedMolecular ConformationMutationParkinson DiseasePathogenesisPenetrancePhosphotransferasesProtein BindingProteinsReportingResearchRisk FactorsTherapeuticTimeVariantWorkage relatedbasedimerleucine-rich repeat kinase 2mutantnew therapeutic targetpreventprotein complex
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Leucine rich repeat kinase 2 (LRRK2) mutations are causal for inherited Parkinsons disease with age-dependent penetrance. The protein is a large complex kinase with several reported protein interactions and mutliple proposed functions. Some mutations increase kinase activity, and the overall aim of this project is to extend our prior observations that kinase activity of LRRK2 is important in pathogenesis association with mutations in this gene.
In the past reporting period, we have spent some time characterizing highly purified LRRK2 protein, and the related homolog LRRK1. We find that both proteins form dimers, which we had previously suggested but has been controversial. One possibility, which we are pursuing, is that there are protein binding partners and/or conformational states of LRRK2 that prevent this from happening within cells. We were also able to confirm our previous observations with partially purified material, that the Parkinson's disease associated LRRK2 protein is a more active kinase than the homolog LRRK1. The significance of this observation is not yet clear.
We have also characterized a risk factor variant for LRRK2, G2385R, which we found surprisingly has lower kinase activity than wild type protein. The likely mechanism is that G2385R alters intramolecular interactions within the large, complex protein. This work may have implications for the types of therapeutics that should be developed for LRRK2-related disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Alpha Synuclein, cellular dysfunction and Parkinson disease
-
批准号:8552517
-
项目类别:
-
资助金额:$17.49万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
Gene expression in the human brain
-
批准号:8736661
-
项目类别:
-
资助金额:$25.35万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
DJ-1 function and oxidative stress
-
批准号:8552528
-
项目类别:
-
资助金额:$34.98万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
Alpha Synuclein, cellular dysfunction and Parkinson disease
-
批准号:8736655
-
项目类别:
-
资助金额:$42.24万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
Alpha Synuclein, cellular dysfunction and Parkinson disease
-
批准号:8931626
-
项目类别:
-
资助金额:$58.45万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
DJ-1 and hexokinases
-
批准号:9552524
-
项目类别:
-
资助金额:$21.14万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
Recessive parkinsonism and mitochondrial function
-
批准号:9351988
-
项目类别:
-
资助金额:$18.25万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
Leucine rich repeat kinase 2 and dominantly inherited Parkinson disease
-
批准号:8335982
-
项目类别:
-
资助金额:$54.47万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
GTPase function of Leucine rich repeat kinase 2
-
批准号:8335973
-
项目类别:
-
资助金额:$33.52万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
GTPase function of Leucine rich repeat kinase 2
-
批准号:10913167
-
项目类别:
-
资助金额:$24.87万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
Genetic Variants Associated with AD/ADRD
-
批准号:10012630
-
项目类别:
-
资助金额:$12.98万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
Alpha Synuclein, cellular dysfunction and Parkinson disease
-
批准号:10005771
-
项目类别:
-
资助金额:$155.9万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
DJ-1 and hexokinases
-
批准号:10005777
-
项目类别:
-
资助金额:$56.3万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
GTPase function of Leucine rich repeat kinase 2
-
批准号:10005770
-
项目类别:
-
资助金额:$97.01万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
Developing a single cell map of the aging human brain relevant to Alzheimer's disease
-
批准号:10688829
-
项目类别:
-
资助金额:$6.7万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
Alpha Synuclein, cellular dysfunction and Parkinson disease
-
批准号:10688880
-
项目类别:
-
资助金额:$116.44万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
DJ-1 function and oxidative stress (Inter-lab project)
-
批准号:10250926
-
项目类别:
-
资助金额:$42.8万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
Genetic Variants Associated with AD/ADRD
-
批准号:10250905
-
项目类别:
-
资助金额:$33.32万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
DJ-1 function and oxidative stress
-
批准号:8148363
-
项目类别:
-
资助金额:$27.5万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
Alpha Synuclein, cellular dysfunction and Parkinson disease
-
批准号:8156800
-
项目类别:
-
资助金额:$5.89万
-
财政年份:--
-
负责人:Mark Cookson
-
依托单位:
国内基金
海外基金
登录
查看更多内容
分化肌细胞脱细胞ECM-cells sheet 3D
支架构建及其促进容积性肌组织缺损再
生修复应用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:肖将尉
-
依托单位:
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
-
批准号:82072862
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2020
-
负责人:徐云升
-
依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
-
批准号:82070825
-
项目类别:面上项目
-
资助金额:53.0万元
-
批准年份:2020
-
负责人:徐西振
-
依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
-
批准号:81903002
-
项目类别:青年科学基金项目
-
资助金额:20.5万元
-
批准年份:2019
-
负责人:王斐斐
-
依托单位:
HA/CD44在乳腺癌转移“先导细胞”(leader cells)侵袭中的作用及机制研究
-
批准号:81402419
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2014
-
负责人:杨翠霞
-
依托单位:
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
-
批准号:81271563
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2012
-
负责人:陈正光
-
依托单位:
树突状细胞(Dendritic cells,DCs)介导的黏膜免疫对猪轮状病毒(PRV)感染的分子作用机制研究
-
批准号:31272541
-
项目类别:面上项目
-
资助金额:82.0万元
-
批准年份:2012
-
负责人:王春凤
-
依托单位:
MTA2在睾丸支持细胞(Sertoli cells)中的功能和机制研究
-
批准号:31271248
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2012
-
负责人:李伟
-
依托单位:
无外源性基因iPS cells向肠细胞分化及对肠损伤的修复
-
批准号:81160050
-
项目类别:地区科学基金项目
-
资助金额:49.0万元
-
批准年份:2011
-
负责人:邵立健
-
依托单位: